Imfinzi

Adult Dosing .

Dosage forms:  INJ

Special Note

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing including toxicity-related dose adjustments

non-small cell lung CA

[resectable disease, neoadjuvant tx, <30 kg]

Dose: 20 mg/kg/dose IV q3wk for up to 4 cycles; Info: for patients with tumor >4cm or node-positive disease with no EGFR or ALK genomic tumor aberrations; part of multi-drug chemo regimen

[resectable disease, neoadjuvant tx, >30 kg]

Dose: 1500 mg IV q3wk for up to 4 cycles; Info: for patients with tumor >4cm or node-positive disease with no EGFR or ALK genomic tumor aberrations; part of multi-drug chemo regimen

[resectable disease, adjuvant tx following neoadjuvant tx, <30 kg]

Dose: 20 mg/kg/dose IV q4wk for up to 12 cycles; Max: 12 cycles; Info: for patients with tumor >4cm or node-positive disease with no EGFR or ALK genomic tumor aberrations

[resectable disease, adjuvant tx following neoadjuvant tx, >30 kg]

Dose: 1500 mg IV q4wk for up to 12 cycles; Max: 12 cycles; Info: for patients with tumor >4cm or node-positive disease with no EGFR or ALK genomic tumor aberrations

[stage III unresectable disease, <30 kg]

Dose: 10 mg/kg/dose IV q2wk x12mo; Max: 12mo; Info: for non-progressive disease after concurrent platinum-based chemo and XRT

[stage III unresectable disease, >30 kg]

Dose: 10 mg/kg/dose IV q2wk x12mo; Max: 12mo; Alt: 1500 mg IV q4wk x12mo, max 12mo; Info: for non-progressive disease after concurrent platinum-based chemo and XRT

[metastatic disease, <30 kg]

Dose: 20 mg/kg/dose IV q3wk x4 cycles on wk 0, 3, 6, 9, then 20 mg/kg/dose IV q4wk starting cycle 5 on wk 12; Info: for patients with no EGFR or ALK genomic tumor aberrations; part of multi-drug chemo regimen

[metastatic disease, >30 kg]

Dose: 1500 mg IV q3wk x4 cycles on wk 0, 3, 6, 9, then 1500 mg IV q4wk starting cycle 5 on wk 12; Info: for patients with no EGFR or ALK genomic tumor aberrations; part of multi-drug chemo regimen

small cell lung CA

[limited stage disease, <30 kg]

Dose: 20 mg/kg/dose IV q4wk x24mo; Max: 24mo; Info: for non-progressive disease after concurrent platinum-based chemo and XRT

[limited stage disease, >30 kg]

Dose: 1500 mg IV q4wk x24mo; Max: 24mo; Info: for non-progressive disease after concurrent platinum-based chemo and XRT

[extensive-stage disease, first-line tx, <30 kg]

Dose: 20 mg/kg/dose IV q3wk x4 cycles as part of multi-drug chemo regimen, then 10 mg/kg/dose IV q2wk as monotherapy

[extensive-stage disease, first-line tx, >30 kg]

Dose: 1500 mg IV q3wk x4 cycles as part of multi-drug chemo regimen, then 1500 mg IV q4wk as monotherapy

biliary tract CA, locally advanced or metastatic

[<30 kg]

Dose: 20 mg/kg/dose IV q3wk for up to 8 cycles as part of multi-drug chemo regimen, then 20 mg/kg/dose IV q4wk as monotherapy

[>30 kg]

Dose: 1500 mg IV q3wk for up to 8 cycles as part of multi-drug chemo regimen, then 1500 mg IV q4wk as monotherapy

hepatocellular CA, unresectable

[<30 kg]

Dose: 20 mg/kg/dose IV x1 on day 1 of cycle 1 with tremelimumab, then 20 mg/kg/dose IV q4wk as monotherapy

[>30 kg]

Dose: 1500 mg IV x1 on day 1 of cycle 1 with tremelimumab, then 1500 mg IV q4wk as monotherapy

mismatch repair deficient endometrial CA, advanced or recurrent

[<30 kg]

Dose: 15 mg/kg/dose IV q3wk x6 cycles as part of multi-drug chemo regimen, then 20 mg/kg/dose IV q4wk as monotherapy

[>30 kg]

Dose: 1120 mg IV q3wk x6 cycles as part of multi-drug chemo regimen, then 1500 mg IV q4wk as monotherapy

muscle invasive bladder CA

[neoadjuvant tx, <30 kg]

Dose: 20 mg/kg/dose IV q3wk x4 cycles; Info: part of multi-drug chemo regimen

[neoadjuvant tx, >30 kg]

Dose: 1500 mg IV q3wk x4 cycles; Info: part of multi-drug chemo regimen

[adjuvant tx following neoadjuvant tx, <30 kg]

Dose: 20 mg/kg/dose IV q4wk for up to 8 cycles; Max: 8 cycles

[adjuvant tx following neoadjuvant tx, >30 kg]

Dose: 1500 mg IV q4wk for up to 8 cycles; Max: 8 cycles

gastric CA, resectable

[neoadjuvant tx, <30 kg]

Dose: 20 mg/kg/dose IV q4wk for up to 2 cycles; Info: for patients with gastric or gastroesophageal junction adenocarcinoma; part of multi-drug chemo regimen

[neoadjuvant tx, >30 kg]

Dose: 1500 mg IV q4wk for up to 2 cycles; Info: for patients with gastric or gastroesophageal junction adenocarcinoma; part of multi-drug chemo regimen

[adjuvant tx following neoadjuvant tx, <30 kg]

Dose: 20 mg/kg/dose IV q4wk for up to 2 cycles as part of multi-drug chemo regimen, then 20 mg/kg/dose IV q4wk for up to 10 cycles as monotherapy; Max: 12 cycles; Info: for patients with gastric or gastroesophageal junction adenocarcinoma

[adjuvant tx following neoadjuvant tx, >30 kg]

Dose: 1500 mg IV q4wk for up to 2 cycles as part of multi-drug chemo regimen, then 1500 mg IV q4wk for up to 10 cycles as monotherapy; Max: 12 cycles; Info: for patients with gastric or gastroesophageal junction adenocarcinoma

renal dosing

[see below]

CrCl >30: no adjustment; CrCl <30: not defined

HD/PD: not defined

hepatic dosing

[see below]

bilirubin 1.1-3x ULN: no adjustment; bilirubin >3x ULN: not defined

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.